AI in drug discovery – what it is, where we stand and the path forward
science.orgPlease. Please let some people with power and influence understand this lesson sooner rather than later. I understand the reasons that's unlikely to occur, but usually the impact isn't quite so drastic and expensive as this is. Just because something is new and shiny doesn't mean that it'll produce the outcomes you need at the other end, and until it's shown that capability your approach to it should be MODERATE.
It's also worth mentioning that drug development timelines typically exceed the interval in which these technologies have been available (or at least effective). Measuring impact will take a long time.
I've been taking it without significant side effects for ~15 years, so I'm not worried, although at this point it's losing its main effect as well.
Wheres my follicles dammit?
its slow-release oral minoxidil formulation called MINX. AI helped with the formulation [1].
its in in similar category as VDPHL01. Hundreds of millions if not a billion dollars has been invested into Veradermics, and their main product is VDPHL01 (also an extended-release oral formulation).
Speak for yourself, if mine goes any lower I’m going to pass out
Only for values of 'all' that exclude well-connected members of the billionaire class and their select associates.
A National Treasure, on the other hand - they enrich life without being a vector for tribalism (eg:Michael Kramer/Kate Reading).
THERE IS INSUFFICIENT DATA TO ANSWER THE QUESTION.
Ketamin should have huge impacts on neuro/brain plasticity when used properly (i.e. in therapy)
In therapy as well.
Same with ketamine. It's not like you can take it a couple of times and open some magic window where everything suddenly becomes easier to learn. From my personal experience and surface-level understanding of the current research, psychedelics(including ketamine) seem to temporarily relax hardened beliefs/priors and rigid neural pathways, which can help you see things from a fresh perspective. But learning something substantial like math or a new language after you've passed the most plastic stages of development is still going to take much longer than what these drugs can realistically help with.
They might make you see something differently or even get you extremely interested in it, but sustaining that interest and consolidating the knowledge or skill is still slow compared with childhood/adolescence. Of course, it depends a lot on what you're learning. For example, crystallized intelligence and sufficient motivation can make some things much easier to learn as an adult, but many useful things are also just boring to learn when you no longer have a childlike plastic brain or an environment built around constant learning.
Edit: Theoretically, you could accelerate learning by taking psychedelics/ketamine at a set frequency but it's a huge gamble because of their risk profile. eg. HPPD/trauma risk with classic psychedelics and bladder/neurotoxicity risk with ketamine if you get addicted or take it too frequently.
No? Well fancy that! :)
I think that was originally linked but got changed to the £30 to Elsevier version for some reason.
It's difficult to calibrate statements made by other scientists unless you're well embedded within a field: Is this someone whose opinions matter? Are they the subject matter expert they make themselves out to be? Is this research itself truly impactful? Is it really 5 years until it will be realized outside of academic labs? Etc...
It's difficult to decipher questions around credibility because they rely on real-world interactions and associations that extend beyond the physical tokens of paper counts, publication venues, citations, and author lists that typically lag behind the front of human knowledge which is generated from real-world interactions. It can be simple things, like the insightful question a grad student, with minimal publication history, asks in a seminar.
Of course, the paywall is also unhelpful too, but a good, brief commentary by an appropriate commentator is a better link for 99% of prospective readers compared to most "peer reviewed" (scare quotes because that's a real question nowadays) articles.
What I was getting at with the issue of credibility is that I (or most others) would have time determining if a particular scholarly author in pharma is a good person to listen to on the subject. But having evidence that Derek Lowe is an honest broker of information in that domain, given his long history of commentary as well as other chemists I know who eagerly read his commentary, I'm willing to defer to his assessment.
eg: August 15, 2026 - https://heathercoxrichardson.substack.com/p/august-15-2026
For example, it helps me install academic software, debug things. It helps me take a large dataset and write scripts to ask questions. It helps me go through experiment drafts to see if I'm missing things. It helps me remember obscure formulas I use every 6 months. It has not, at least in my experience, come up with anything truly novel.
A concrete example: AlphaFold is great...to come up with a starting model for a chimeric fusion or something. What would have taken me 1-2 hours fumbling around in PDB or CIF files is now a quick prompt.
is it all the work? no, but it's a part that's early on and have high perceived impact.
then, as you progress, that tool actually gets in the way and a new feature that would take 2 hours, now is around 2 days.
Though in some areas where I can sustain interest, AI is helping me go deeper. For instance, I've been putting myself to sleep at night by just asking it questions about expectation maximization and Bayesian statistics. This has seriously boosted my understanding of cryo-EM alignment algorithms in a way I couldn't do in grad school because there was no professor that understood enough to help me when I got stuck reading literature.
So it's a double edged sword for sure.
I have a co-worker who doesnt feel like ADHD helps him because he sits down and just starts... doing work and typing. Assign him a complex task, he will just start on it. Mind blowing he does this day in and day out. an absolute machine.
Im guessing this isnt code that needs to "scale", that needs to "be elegant", that you arent focused on maintainability for the next decade. That its built for purpose and left behind.
Its all the code that for a programer would normally be in this matrix https://xkcd.com/1205/ (is it worth your time) -
I think that (understandably) HN is full of professional programmers for whom code is the product, and so LLMs are often viewed through that lens. But for someone like me, a drug is the product, not code. One off vibe coded slop is both fine, and often an upgrade over the academic software I was using.
For instance, last week I took a piece of software that decompresses a TIFF file and multithreaded it for an almost 4x speedup. I'd always known it was single threaded and it irked me because I could see my pipelines waiting for it to catch up, but I never had the expertise in C++ to go fix it. Claude did it in 30 minutes and I didn't even have to go through the hassle of compiling it again - it did that too.
What I don't know is, if someone wasn't in the trenches for a decade learning how computers work, would the results be as good?
The lack of comparable data and testability really does seem to be a challenge. I wonder if people would be more willing to collect and share lots of health data if the collecting company was a non-profit dedicated to anonymizing it.
A) no education
B) no resources
C) not smart enough to be a self-taught bio-hacker
Everyone hears "AI is going to cure disease" and pictures some cure-all pill from a bio lab which is what I feel this paper is hinting at is missingb but that's the top of the funnel; I'm at the bottom where patients live and that is where AI is already quietly working. Its just not being benchmarked.
I built https://crohns.ai. I set out to make an AI-native clinical-trial manager with a feedback loop (DDP) and ended up somewhere completely different: instead of chasing a new "drug" which is totally out of my grasp; financially, intellectually etc... I used it to codify a care protocol that helped me avoid a flare after I got laid off, lost my insurance, and lost access to Skyrizi.
How are those biologics? Did you have to visit the doctor to get injections frequently?
The 1st 2 injections where done by a nurse that came to my home, the others were done as self injections using their njection kits.
Intent: https://wiki.crohns.ai/agent/posts/ibd-biologic-switch-decis...
Program: https://crohns.ai/program/71168-biologic-therapy-initiation
Protocol: https://crohns.ai/protocol/71168
If given the chance, I might go back on it because my protocol can be a little strict at times but either way I do see a significant shift to tools like this given the state of the US Healthcare system.
This is the problem with AI for all of science - not just drug discovery. Applied ML has spread like wildfire through academia over the past decade - this started well before the LLM hype. It’s the perfect honey trap: research is painstaking and slow, ML offered a shortcut, and best of all, it just needs data. Research produces lots and lots of data! Surely this will be a match made in heaven.
I’ve watched the same pattern play out at least four or five times now in various roles.
(1) Propose an ML-guided approach to material/chemistry discovery/optimization.
(2) Gather existing data (real, experimental data).
(3) Realize there’s less than about 50 true rows of data on the outputs of interest.
At this point, you either: (4a) revert to traditional methods but keep the veneer of using ML to save face, or (4b) pivot to computational/simulation work or a high-throughput system that’s very far removed from your original problem, but allows you to keep playing with ML toys
It’s really bad. I left the industry. I don’t know how long it will take for people doing real science to take back the reins (and the funding).
Thus the reticence of science-oriented companies to invest heavily in these mass data-gathering exercises to feed ML. It’s damn expensive, and almost always leads you back to raw data issues, not breakthrough discovery. Doing it without a set purpose in mind is even more likely to yield garbage.
You can do more tests on smaller things, like checking if some protein will kill some cells of a pest, but making sure a plant produces it enough that it actually does something significant to the real, live pests, that it's not toxic, and it doesn't harm the plant's yield massively (as it's now spending time producing your pesticide) is still going to take years. We might be able to fold proteins, but the kind of things we'd need to really simulate plant biology well enough to not need years of failures are still very far away.
And it's far worse in medicine, as with plants at least nobody has ethical concerns if they fail and die, and nobody needs to get consent from a corn seed. Getting to 50 actual data points from many medical studies is already a lot of effort. And imagine when it's a long term study, and you need to follow patients for 30 years, as theym move, or die, or decide to stop participating, or who knows what.
https://patwalters.github.io/Response-to-Peter-Kenny/
> (4a) revert to traditional methods but keep the veneer of using ML to save face
I haven't worked in the industry side of things but in academia everyone kind of agrees that gradient boosting trees are some of the best models to do these things.
What hasn’t changed is finding ones that are manufacturable/synthesizable.
Even if you find 1 million new stable molecules, there no guarantee that even one of them is manufacturable.
>clinically relevant impact is, so far, disappointingly limited
it could be that the AI tools have to get to some threshold before they are very useful? Like with the Economist talking to Hassabis:
>AlphaFold itself took six years of work to predict its first protein structure, and then one year to follow up with what he describes as the structures of “all 200m proteins known to science”. He hopes a similar speedup will happen inside Isomorphic.